Anorexia: Aetiology, epidemiology and management in older people

Drugs and Aging

Volumn 26, Issue 7, 2009, Pages 557-570

  Thomas, David R ^a  

^a Division of Geriatric Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; AMYLIN; BOMBESIN; CHOLECYSTOKININ; CORTICOSTEROID; CYPROHEPTADINE; CYTOKINE; DOPAMINE; DRONABINOL; HUMAN GROWTH HORMONE; ICOSAPENTAENOIC ACID; INSULIN; MEDROXYPROGESTERONE; MEGESTROL; MEGESTROL ACETATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NABILONE; NEUROMEDIN B; NEUROTENSIN; OXANDROLONE; OXYTOCIN; PENTOXIFYLLINE; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; SOMATOMEDIN C; TESTOSTERONE; THALIDOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADVERSE OUTCOME; AGE DISTRIBUTION; ALZHEIMER DISEASE; ANOREXIA; ANOREXIA NERVOSA; ARTHRALGIA; BEDTIME DOSAGE; BEHAVIOR DISORDER; BODY WEIGHT; BURN; CACHEXIA; CANCER PATIENT; CARPAL TUNNEL SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DEMENTIA; DENTAL HEALTH; DEPRESSION; DIABETES CONTROL; DIET SUPPLEMENTATION; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DRUG FATALITY; DRUG MEGADOSE; EDEMA; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; EVENING DOSAGE; EXERCISE; FOOD INTAKE; FOOD PREFERENCE; FRACTURE; FUNCTIONAL STATUS; GASTRITIS; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DEFICIENCY; IMPOTENCE; INFECTION; MALABSORPTION; MALNUTRITION; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; NUTRITIONAL STATUS; PARANOIA; PATHOPHYSIOLOGY; POVERTY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; REHABILITATION CARE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SOCIAL ASPECT; SOCIAL ISOLATION; SOCIOLOGY; VAGINA BLEEDING; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; WASTING SYNDROME; WEIGHT GAIN; WOUND;

AGED; AGED, 80 AND OVER; ANIMALS; ANOREXIA; APPETITE REGULATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGICAL PROCESSES;

EID: 70349088176     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11316360-000000000-00000     Document Type: Review

References (133)

1. Murden RA, Ainslie NK. Recent weight loss is related to short-term mortality in nursing homes. J Gen Intern Med 1994; 9 (11): 648-650
2. Weinsier RL, Hunker EM, Krumdieck CL, et al. Hospital malnutrition: a prospective evaluation of general medical patients during the course of hospitalization. Am J Clin Nutr 1979; 32 (2): 418-426
3. Morley JE, Thomas DR. Anorexia and aging: pathophysiology. Nutrition 1999; 15 (6): 499-503
4. Morley JE. Decreased food intake with aging. J Gerontol A Biol Sci Med Sci 2001; 56: 81-88
5. Roberts SB, Fuss P, Heyman MB, et al. Control of food intake in older men. JAMA 1994; 272: 1601-1606
6. Morley JE. Anorexia, sarcopenia, and aging. Nutrition 2001; 17: 660-663
7. Morley JE. Anorexia in older persons: epidemiology and optimal treatment. Drugs Aging 1996; 8 (2): 134-155
8. McGandy RB, Barrows Jr CH, Spanias A, et al. Nutrient intake and energy expenditure in men of different ages. J Gerontology 1966; 21: 581-587
9. Ritchie CR, Thomas DR. Aging. In: Heimburger DC, Weinsier RL, editors. Handbook of clinical nutrition. 3rd ed. St Louis (MO): Mosby, 1997
10. Abraham S, Carroll MD, Dresser CM, et al. Dietary intake of persons 1-74 years of age in the United States. Advance data from Vital and Health Statistics of the National Center for Health Statistics no. G. Rockville (MD): Public Health Service, 1977 Mar 30
11. De Castro JM. How can eating behavior be regulated in the complex environments of free-living humans? Neurosci Biobehav Rev 1996; 20: 119-131
12. Thomas DR. Unintended weight loss in older adults. Aging Health 2008; 4 (2): 191-200
13. Thomas DR. Nutritional requirements in older adults. Chapter 6. In: Morley JE, Thomas DR, editors. Geriatric nutrition. Boca Raton (FL): CRC Press, 2007: 131-136
14. Doty RL, Shaman P, Applebaum SL, et al. Smell identification ability: changes with age. Science 1984; 226: 1441-1443
15. Schiffman S. Food recognition by the elderly. J Gerontol 1977; 32: 586-592
16. Buckler DA, Kelber ST, Goodwin JS. The use of dietary restrictions in malnourished nursing home patients. J Am Geriatr Soc 1994; 42: 1100-1102
17. Tariq S, Karcic E, Thomas DR, et al. The use of a no-concentrated-sweets diet in the management of type 2 diabetes in nursing home patients. J Am Diet Assoc 2001; 101 (12): 1463-1466
18. Morley JE, Silver AJ. Anorexia in the elderly. Neurobiol Aging 1988; 9: 9-16
19. Morley JE. Decreased food intake with aging. J Gerontol A Biol Sci Med Sci 2002; 57 (1): M2-6
20. Donini LM, Savina C, Cannella C. Eating habits and appetite control in the elderly: the anorexia of aging. Int Psychogeriatr 2003; 15: 73-87
21. Hotaling DL. Nutritional considerations for the pureed diet texture in dysphagic elderly. Dysphagia 1992; 7: 81-85
22. Johnson RM, Smiciklas-Wright H, Soucy IM, et al. Nutrient intake of nursing home residents receiving pureed foods or a regular diet. J Am Geriatr Soc 1995; 43: 344-348
23. Kayser-Jones J. Mealtime in nursing homes: the importance of individualized care. J Gerontol Nurs 1996; 22: 26-31
24. Fitten LJ, Morley JE, Gross PI, et al. Depression. J Am Geriatr Soc 1989; 37 (5): 459-472
25. Blaum CS, Fries BE, Fiatarone MA. Factors associated with low body mass index and weight loss in nursing home residents. J Gerontol 1995; 50: M162-8
26. Kaye WH, Klump KL, Frank GKW, et al. Anorexia and bulimia nervosa. Annu Rev Med 2000; 51: 299-313
27. Plata-Salaman CR. Anorexia during acute and chronic disease. Nutrition 1996; 12 (2): 69-78
28. Hedlund J, Hansson LO, Ortqvist A. Short-and long-term prognosis for middle-aged and elderly patients hospitalized with community-acquired pneumonia: impact of nutritional and inflammatory factors. Scand J Infect Dis 1995; 27 (1): 32-37
29. Plata-Salaman CR. Anorexia during acute and chronic disease. Nutrition 1996; 12: 69-76
30. Mowe M, Bohmer T, Kindt E. Reduced nutritional status in an elderly population (>70 y) is probable before disease and possibly contributes to the development of disease. Am J Clin Nutr 1994; 59 (2): 317-324
31. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27 (6): 793-799
32. Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123-136
33. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-763
34. Seruga B, Zhang H, Bernstein LJ, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8 (11): 887-899
35. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4: 686-694
36. Illman J, Corringham R, Robinson Jr D, et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 2005; 3: 37-50
37. Rote NS. Inflammation. In: McCance KL, Huether SE, editors. Pathophysiology: the biological basis for disease in adults and children. St Louis (MO): Mosby, 1998: 205-236
38. Plata-Salaman CR. Strategies for potential manipulation of anorexia during acute and chronic disease. Nutrition 1995; 11: 702-704
39. Espat NJ, Moldawer LL, Copeland 3rd EM. Cytokinemediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients. J Surg Oncol 1995; 58: 77-82
40. Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr 2007; 26 (4): 389-399
41. Westerblad H, Allen DG. Recent advances in the understanding of skeletal muscle fatigue. Curr Opin Rheumatol 2002; 14 (6): 648-652
42. Mitch WE. Mechanisms causing loss of lean body mass in kidney disease. Am J Clin Nutr 1998; 67: 359-366
43. Toth MJ, Gottlieb SS, Goran MI, et al. Daily energy expenditure in free-living heart failure patients. Am J Physiol 1997; 272: 469-475
44. Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-2386
45. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985; 42: 1255-1265
46. Donini LM, Savina C, Piredda M, et al. Senile anorexia in acute-ward and rehabilitation settings. J Nutr Health Aging 2008; 12 (8): 511-517
47. Serra Prat M, Fernandez X, Ribo L, et al. Loss of appetite in elderly people in the community and its relationship with functional capacity. Med Clin (Barc) 2008; 130 (14): 531-533
48. Milne AC, Potter J, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2002; (3): CD003288
49. Lauque S, Arnaud-Battandier F, Mansourian R, et al. Protein-energy oral supplementation in malnourished nursing-home residents: a controlled trial. Age Aging 2000; 29: 51-56
50. Guigoz Y, Vellas B. Assessing the nutritional status of the elderly: the Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1998; 54: S59-65
51. Keller HH, McKenzie JD, Goy RE. Construct validation and test-retest reliability of the seniors in the community: risk evaluation for eating and nutrition questionnaire. J Gerontol A Biol Sci Med Sci 2001; 56: M552-8
52. Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the functional assessment of anorexia/ cachexia therapy (FAACT) questionnaire. Qual Life Res 2001; 9: 1137-1146
53. Thomas DR. Nutritional Assessment in long term care. Nutr Clin Pract 2008; 23: 383-387
54. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A: 1326-1336
55. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000; 88: 2164-2171
56. Cella DF, VonRoenn J, Lloyd S, et al. The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia/cachexia. Qual Life Res 1995; 4: 221-231
57. Mathey MF. Assessing appetite in Dutch elderly with the Appetite, Hunger and Sensory Perception (AHSP) questionnaire. J Nutr Health Aging 2001; 5: 22-28
58. Wilson MM, Thomas DR, Rubenstein LZ, et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr 2005; 82 (5): 1074-1081
59. Thomas DR. Management of protein-energy under-nutrition in older adults, chapter 16. In: Morley JE, Thomas DR, editors. Geriatric nutrition. Boca Raton (FL): CRC Press, 2007: 267-290
60. Thomas DR. Causes of protein-energy malnutrition. In: Seiler WO, Stai helin HB, editors. Malnutrition in the elderly. Darmstadt: Steinhopff Verlag, 1999: 59-68
61. Thomas DR, Ashmen W, Morley JE, et al. Nutritional management in long-term care: development of a clinical guideline. J Gerontol A Biol Sci Med Sci 2000; 55: M725-34
62. Wilson MM, Vaswani S, Liu D, et al. Prevalence and causes of undernutrition in medical outpatients. Am J Med 1998; 104: 56-63
63. Schiffman SS, Warwick ZS. Effect of flavor enhancement of foods for the elderly on nutritional status: food intake, biochemical indices, and anthropometric measures. Physiol Behav 1993; 53: 395-402
64. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983; 17: 37-49
65. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 11S: 37-41
66. Gelenberg AJ, Laukes C, McGahuey C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000; 61: 356-360
67. Carpenter LL, Leon Z, Yasmin S, et al. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999; 11: 81-86
68. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999; 60: 45-49
69. Gants R. Detection and correction of underweight problems in nursing home residents. J Gerontol Nurs 1997; 23: 26-31
70. Dawe D, Moore-Orr R. Long-intensity range of motion exercise: invaluable nursing care for elderly patients. J Adv Nurs 1995; 21: 675-681
71. Ruuskanen JM, Ruoppila I. Physical activity and physiologic well being among people 65-84 years. Age Ageing 1995; 24: 292-296
72. Fiatarone MA, Marks EC, Ryan ND, et al. High-intensity training in nonogenarians: effects on skeletal muscle. JAMA 1990; 263: 3029-3034
73. Johnson LE, Dooley PA, Gleick JB. Oral nutritional supplement use in elderly nursing home patients. J Am Geriatr Soc 1993; 41: 947-952
74. Elmstahl S, Steen B. Hospital nutrition in geriatric long-term care medicine: II. Effects of dietary supplements. Age Ageing 1987; 16: 73-80
75. Wilson MM, Purushothaman R, Morley JE. Effect of liquid dietary supplements on energy intake in the elderly. Am J Clin Nutr 2002; 75 (5): 944-947
76. Milne AC, Avenell A, Potter J. Meta-analysis: protein and energy supplementation in older people. Ann Intern Med 2006; 144 (1): 37-48
77. Lauque S, Arnaud-Battandier F, Gillette S, et al. Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer's disease at risk of malnutrition: a prospective randomized study. J Am Geriatr Soc 2004; 52 (10): 1702-1707
78. Thomas DR. Guidelines for the use of orexigenic drugs in longterm care. Nutr Clin Pract 2006; 21 (1): 82-87
79. Moertel C, Schutt AG, Reiteneier RJ, et al. Corticosteroid therapy of pre-terminal gastrointestinal cancer. Cancer 1974; 33: 1607-1609
80. Willox J, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984; 288 (6410): 27
81. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double blind study. Cancer Treat Rep 1985; 69: 751-754
82. Robusteli Della Cuna G, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in pre-terminal cancer patients: a placebo controlled multicenter study. Eur J Cancer Clin Oncol 1989; 25: 1823-1829
83. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989; 25: 1823-1824
84. Nelson K, Walsh D, Deeter P, et al. A phase II study of delta-nine-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994; 10: 14-18
85. Kardinal C, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990; 65: 2657-2662
86. Tchekmedyian S, Tait N, Moody M, et al. High dose megestrol acetate: a possible treatment of cachexia. JAMA 1987; 257: 1195-1199
87. Cruz JM, Muss HB, Brockschmidt JK, et al. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard vs. a high does therapy. Semin Oncol 1990; 17 Suppl.: 63-67
88. Bruerra E, Macmillan K, Hanson J, et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66: 1279-1282
89. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer, anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127-1132
90. Schmoll E, Wilke H, Thole R. Megestrol acetate in cancer cachexia. Semin Oncol 1991; 1 Suppl. 2: 32-34
91. Heckmayr M, Gatzenneier U. Treatment of cancer weight loss in patients with advanced lung cancer. Oncology 1992; 49 Suppl. 2: 32-34
92. Feliu J, Gonzalez-Baron M, Berrocal A. Usefulness of megestrol acetate in cancer cachexia and anorexia. Am J Clin Oncol 1992; 15: 436-440
93. Azona C, Castro L, Crespo E, et al. Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumors. Aliment Pharmacol Ther 1996; 10 (4): 577-586
94. Mantovani G, Maccio A, Bianchi A, et al. Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995; 25: 135-141
95. Tchekmedyian S, Hakman M, Siau J, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992; 69: 1268-1274
96. Beller E, Tattersail M, Lumley T, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomized placebo-control trial. Ann Oncol 1997; 8: 277-283
97. Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2 (2): 74-78
98. Fietkau R, Riepl M, Kettner H. Supportive use of megestrol acetate in patients with head and neck cancer during radio (chemo)therapy. Eur J Cancer 1997; 33: 75-79
99. McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79: 495-500
100. Gebbia V, Testa A, Gebbia N. Prospective randomized trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 1996; 73 (12): 1576-1580
101. Plassee TF, Gorter RW, Krasnow SH, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695-700
102. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14: 7-14
103. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group Study. J Clin Oncol 1002; 20: 567-573
104. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 913-919
105. Gonzalez-Rosales F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manage 1997; 14: 311-314
106. Reyes-Teran G, Sieira-Madero JG, Martinez Del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501-1507
107. Standards options and recommendations for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC). Bull Cancer 2000; 87: 315-328
108. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22: 2469-2476
109. Morley JE, Kaiser FE, Perry HM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410-413
110. Morley JE, Distiller LA, Lissoos I, et al. Testicular function in patients with spinal cord damage. Horm Metab Res 1979; 11: 679-682
111. Rudman D, Mattson DE, Nagraj HS, et al. Plasma testosterone in nursing home men. J Clin Epidemiol 1988; 41: 231-236
112. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-2677
113. Morley JE, Perry 3rd HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149-152
114. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-1667
115. Borst SE, Mulligan T. Testosterone replacement therapy for older men. Clin Interv Aging 2007; 2 (4): 561-566
116. Hengge UR, Baumann M, Maleba R, et al. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 1996; 75 (1): 129-138
117. Pengelly CD. Oxymetholone in the chemotherapy of malignant disease. Curr Med Res Opin 1973; 1 (7): 401-406
118. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 873-882
119. Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991; 39: 235-240
120. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785-792
121. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metabol Care 2005; 8: 265-269
122. Yeh SS, Wu SY, Levine DM, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol A Biol Sci Med Sci 2001; 56: M48-54
123. Yeh SS, Hafner A, Schuster MW, et al. Relationship between body composition and cytokines in cachectic patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2003; 51: 1365-2389
124. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540-545
125. Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52: 1479-1486
126. Yarasheski KE. Growth hormone effects on metabolism, body composition, muscle mass, and strength. Exerc Sport Sci Rev 1994; 22: 285-312
127. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005 Apr 18; (2): CD004310
128. Loprinzi C, Jensen M, Jiang N, et al. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 1992; 67: 1160-1162
129. Koller E, Gibert C, Green L, et al. Thrombotic events associated with megestrol acetate in patients with AIDS cachexia. Nutrition 1999; 15: 294-298
130. Thomas DR. Incidence of venous thromboembolism in megestrol acetate users. J Am Med Dir Assoc 2004; 5: 65-67
131. Hansson PO, Welin L, Tibblin G, et al. Deep vein thrombosis and pulmonary embolism in the general population. Arch Intern Med 1997; 157: 1665-1670
132. Kniffin Jr WD, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1992; 232: 155-160
133. Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thrombotic disorders: an international case control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312 (7023): 83-88